These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 1810495)

  • 1. [The antitumor activity of liposomal aclarubicin in vitro and in vivo].
    Viadro MM; Navashin SM
    Biull Eksp Biol Med; 1991 Nov; 112(11):523-5. PubMed ID: 1810495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental antimetastatic activity of aclarubicin].
    Viadro MM; Terent'eva TG
    Antibiot Khimioter; 1988 Nov; 33(11):845-8. PubMed ID: 3228327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of toxicity and antitumor activity of original and reproduced anthracycline drugs.
    Kuśnierczyk H; Radzikowski C; Górecki P; Cichocka K
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):51-62. PubMed ID: 7503636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of avermectins.
    Drinyaev VA; Mosin VA; Kruglyak EB; Novik TS; Sterlina TS; Ermakova NV; Kublik LN; Levitman MKh; Shaposhnikova VV; Korystov YN
    Eur J Pharmacol; 2004 Oct; 501(1-3):19-23. PubMed ID: 15464058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
    Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
    Park YS; Hakomori S; Kawa S; Ruan F; Igarashi Y
    Cancer Res; 1994 Apr; 54(8):2213-7. PubMed ID: 8174128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
    Daoud SS; Juliano RL
    Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
    Boman NL; Masin D; Mayer LD; Cullis PR; Bally MB
    Cancer Res; 1994 Jun; 54(11):2830-3. PubMed ID: 8187061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
    Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
    Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
    Ahmad I; Filep JJ; Franklin JC; Janoff AS; Masters GR; Pattassery J; Peters A; Schupsky JJ; Zha Y; Mayhew E
    Cancer Res; 1997 May; 57(10):1915-21. PubMed ID: 9157985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
    Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
    J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
    Li LH; Wallace TL; Richard KA; Tracey DE
    Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
    Egorov LV; Terent'eva TG; Rudneva NA; Egorenko GG; Ivanitskaia LP
    Antibiot Med Biotekhnol; 1985 Dec; 30(12):918-27. PubMed ID: 3866512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Induction of the tumoricidal activity of human and murine peritoneal macrophages under the action of antitumor chemical preparations].
    Potapov SL; Viadro MM
    Biull Eksp Biol Med; 1989 Sep; 108(9):330-2. PubMed ID: 2611394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
    Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
    Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
    Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
    Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.